نجحت شركة @TolemyBio في جمع تمويل ما قبل التأسيس بقيمة 1.4 مليون يورو، بهدف تسريع تطوير منصة Orbit المعتمدة على الذكاء الاصطناعي، والمصممة لمساعدة العلماء على فهم الأنظمة الخلوية وتوجيهها بكفاءة أعلى.
. @TolemyBio closes a €1.4 million funding round with participation from, among others, Big Sur Ventures, Norrsken Evolve, JME Ventures, Masia and Redbus Ventures https://t.co/upF2KVUXFb
. @TolemyBio cierra una ronda de €1,4 millones con la participación, entre otros, de Big Sur Ventures, Norrsken Evolve, JME Ventures, Masia y Redbus Ventures https://t.co/ZvMbN7TyiG
Big moment @TolemyBio , we’ve raised €1.4M to build the control panel for the cell!
At Tolemy, we’re building Orbit: an AI-native platform for understanding, predicting and directing cellular systems.
If you want to build meaningful tools for biology, come and join us!
Today marks a major milestone for us at Tolemy!
We’ve raised a €1.4M pre-seed to build Orbit: the control panel for the cell.
Orbit is an AI-native platform helping scientists understand, predict and direct cellular systems.
Now, to scale the platform, partnerships and team!
Tolemy Bio secures $1.4M to turn messy lab data into AI-ready intelligence💲
@TolemyBio is a Cambridge-based biotech startup building an AI-enabled control panel for cell biology, addressing the persistent bottleneck in drug development, where experimental data is scattered across spreadsheets, lab equipment, notebooks, and disconnected files.
The startup has secured $1.4 million in pre-seed funding, led by Norrsken Evolve, with participation from Big Sur Ventures, JME Ventures, Masia, and a new, undisclosed UK stealth fund.
Read more here: https://t.co/e3bizmyOFQ
#StartupsMagazine